ArticleOncology letters2025
AMIGO2 expression at the invasive front of bladder cancer predicts recurrence-free and overall survival after radical cystectomy.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AMIGO2 accelerates tumor progression by inducing a cancer stem cell-like phenotype.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is a leading cause of cancer-related mortality worldwide, partly due to the absence of reliable biomarkers for the accurate prediction of patient prognosis. Amphoterin-induced gene and open reading frame 2 (AMIGO2) expression is a prognostic factor in several types of cancer. The present study aimed to clarify whether AMIGO2 expression can predict the prognosis of patients with bladder cancer. This retrospective study included patients with primary bladder cancer who underwent radical cystectomy at Tottori University Hospital (Yonago, Japan) and its affiliated hospitals between January 2010 and December 2017. Tumor tissues and data were collected from 100 patients and immunohistochemical analysis was performed. The independent predictors in multivariate analysis were lymph node metastasis for recurrence-free survival (RFS), and AMIGO2 expression and pathological T stage for overall survival (OS). Furthermore, AMIGO2 expression was evaluated at the invasive tumor front, and it was revealed that AMIGO2 expression was an independent prognostic factor for both RFS and OS, in addition to lymph node metastasis for RFS. Ki-67 expression, a marker of cell proliferation that is also associated with poor prognosis in several types of cancer, was examined, and Ki-67 expression and lymph node metastasis were identified as independent prognostic factors in RFS, but not in OS. However, the co-expression of AMIGO2 and Ki-67 was identified as an independent prognostic factor for OS. In conclusion, AMIGO2 expression may be considered a novel biomarker for the identification of the risk of recurrence and reduced survival in patients with bladder cancer, and could be used as a rationale for initiating treatment, such as radiation therapy, chemotherapy or immunotherapy, after radical cystectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.